Candriam Luxembourg S.C.A. decreased its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 40.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 160,000 shares of the biopharmaceutical company’s stock after selling 110,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Sangamo Therapeutics were worth $1,408,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the stock. Aperio Group LLC bought a new stake in Sangamo Therapeutics during the second quarter worth $108,000. Fox Run Management L.L.C. bought a new stake in Sangamo Therapeutics during the second quarter worth $126,000. Metropolitan Life Insurance Co. NY increased its stake in Sangamo Therapeutics by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 780 shares during the last quarter. Gilder Gagnon Howe & Co. LLC bought a new stake in Sangamo Therapeutics during the first quarter worth $154,000. Finally, Bank of America Corp DE increased its stake in Sangamo Therapeutics by 49.9% in the first quarter. Bank of America Corp DE now owns 32,625 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 10,861 shares during the last quarter. 58.25% of the stock is currently owned by institutional investors.

Sangamo Therapeutics, Inc. (NASDAQ SGMO) opened at 10.25 on Friday. The firm’s market capitalization is $737.37 million. The stock has a 50 day moving average price of $9.08 and a 200 day moving average price of $6.17. Sangamo Therapeutics, Inc. has a one year low of $2.65 and a one year high of $10.50.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The business had revenue of $8.30 million for the quarter, compared to analyst estimates of $5.82 million. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. The firm’s revenue for the quarter was up 124.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.38) EPS. On average, equities analysts predict that Sangamo Therapeutics, Inc. will post ($0.98) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/13/candriam-luxembourg-s-c-a-sells-110000-shares-of-sangamo-therapeutics-inc-nasdaqsgmo.html.

SGMO has been the topic of a number of recent research reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $17.00 price objective on shares of Sangamo Therapeutics in a report on Thursday, June 22nd. ValuEngine raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Friday. Piper Jaffray Companies set a $8.00 price objective on Sangamo Therapeutics and gave the company a “hold” rating in a report on Thursday. BidaskClub downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Finally, Zacks Investment Research downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $9.67.

In related news, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $10.00, for a total transaction of $150,000.00. Following the sale, the vice president now owns 35,517 shares in the company, valued at approximately $355,170. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 8.10% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics, Inc. (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.